Lilly Tells Physicians To Have Patience With Strattera
This article was originally published in The Pink Sheet Daily
Executive Summary
The company's efforts to re-energize the brand include an increased focus on atomoxetine's delayed onset of action in its professional detailing. Lilly also expects increased penetration of the adult ADD market to help boost Strattera's market share.